title: Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice.
abstract: Poly(lactide-co-glycolide) (PLG) microspheres were tested as a parenteral delivery system for human beta-amyloid (1-42) (Abeta), a potential immunotherapeutic undergoing assessment in Phase 1 studies for Alzheimer's disease (AD). Abeta was successfully encapsulated in PLG microspheres of average sizes of 3 or 15 microm diameter. Swiss Webster (SW) mice were injected by the sub-cutaneous (s.c.) or intra-peritoneal (i.p.) routes with 3-33 microg Abeta. Abeta-PLG microparticles (3 microm) induced dose-dependent antibody responses, which were maximal at 33 microg Abeta, while Abeta in phosphate-buffered saline (PBS) produced weak antibody responses at the same doses by both routes. Significantly increased antibody responses were seen for both small and large particle formulations given by the i.p. route in comparison to the s.c route. It was previously reported that passive immunisation with Abeta-specific antibodies cleared amyloid plaques in a mouse model of AD (Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med 2000;6:916-19), an indication that induction of serum antibody is a prerequisite for efficacy.
authors.affiliation: Elan Biotechnology Research, Biotechnology Building, Trinity College, 2, Dublin, Ireland. dbrayden@elancorp.com
authors.forename: D J
authors.initials: DJ
authors.lastname: Brayden
authors.forename: L
authors.initials: L
authors.lastname: Templeton
authors.forename: S
authors.initials: S
authors.lastname: McClean
authors.forename: R
authors.initials: R
authors.lastname: Barbour
authors.forename: J
authors.initials: J
authors.lastname: Huang
authors.forename: M
authors.initials: M
authors.lastname: Nguyen
authors.forename: D
authors.initials: D
authors.lastname: Ahern
authors.forename: R
authors.initials: R
authors.lastname: Motter
authors.forename: K
authors.initials: K
authors.lastname: Johnson-Wood
authors.forename: N
authors.initials: N
authors.lastname: Vasquez
authors.forename: D
authors.initials: D
authors.lastname: Schenk
authors.forename: P
authors.initials: P
authors.lastname: Seubert
mesh_terms: D016229:Amyloid beta-Peptides / Q000008:administration & dosage* / Q000276:immunology; D000818:Animals; D000906:Antibodies / Q000097:blood*; D001673:Biodegradation, Environmental; D004306:Dose-Response Relationship, Immunologic; D007114:Immunization; D051379:Mice; D008863:Microspheres; D010316:Particle Size; D011098:Polyglactin 910 / Q000008:administration & dosage*
chemical_list: D016229:Amyloid beta-Peptides; D000906:Antibodies; D011098:Polyglactin 910